Inovio stock surges after experimental Covid-19 vaccine shows long-term protection in animals
Excerpt from the article:
“Inovio’s stock climbed as much as 15% in pre-market trading Thursday after the Montgomery County biopharmaceutical company announced its Covid-19 vaccine candidate was effective in protecting non-human primates from the virus 13 weeks after the last vaccination.
The stock was up more than 6% to $20.73 per share at Thursday’s close.
According to the company, its experimental DNA-based vaccine, INO-4800, showed durable antibody and T cell responses in rhesus macaques, a monkey species, for four months.”
Click the button below to read the Article:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?